[A23-10] Emicizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2023
Project no.:
A23-10
Commission:
Commission awarded on 22.02.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Haematology
Routine prophylaxis of bleeding episodes in patients of all age groups with haemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors who have moderate disease (factor VIII ≥ 1% and ≤ 5%) with severe bleeding phenotype
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-26 | Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-20 | Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V | Commission completed |